{"id":22529,"date":"2022-10-21T14:23:01","date_gmt":"2022-10-21T12:23:01","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=22529"},"modified":"2022-10-21T14:23:01","modified_gmt":"2022-10-21T12:23:01","slug":"lipum-ab-publ-har-genomfort-en-riktad-emission","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/lipum-ab-publ-har-genomfort-en-riktad-emission\/","title":{"rendered":"Lipum AB (publ) har genomf\u00f6rt en riktad emission"},"content":{"rendered":"<p class=\"preamble\">Lipum har genomf\u00f6rt en riktad emission om cirka 39 MSEK till vissa befintliga och nya investerare med ett uttalat l\u00e5ngsiktigt intresse i bolaget.<\/p>\n<p>Emissionslikviden avses prim\u00e4rt anv\u00e4ndas f\u00f6r finansiering av bolagets fas I-studie samt f\u00f6r ut\u00f6kade prekliniska studier av den biologiska l\u00e4kemedelskandidaten SOL-116.<\/p>\n<p>Lipum \u00e4r ett biofarmaceutiskt bolag specialiserat p\u00e5 uppt\u00e4ckt och utveckling av ny behandling f\u00f6r kroniska inflammatoriska sjukdomar. L\u00e4kemedelskandidaten SOL-116 \u00e4r en humaniserad antikropp som ska ge s\u00e4krare och effektivare behandling genom att blockera en tidigare f\u00f6rbisedd m\u00e5lmolekyl i immunf\u00f6rsvaret (BSSL). Lipums aktier \u00e4r noterade p\u00e5 Nasdaq First North Growth Market (LIPUM).<\/p>\n<p>Lipum r\u00e5dgavs av Mannheimer Swartling i transaktionen.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lipum har genomf\u00f6rt en riktad emission om cirka 39 MSEK till vissa befintliga och nya investerare med ett uttalat l\u00e5ngsiktigt intresse i bolaget. Emissionslikviden avses\u2026<\/p>\n","protected":false},"author":16,"featured_media":22531,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-22529","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uppdrag","business-group-publik-ma-och-aktiemarknad"],"acf":[],"lang":"sv","translations":{"sv":22529,"en":22534},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/22529"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=22529"}],"version-history":[{"count":2,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/22529\/revisions"}],"predecessor-version":[{"id":22533,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/22529\/revisions\/22533"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/22531"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=22529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=22529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=22529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}